BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 38451314)

  • 21. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
    Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
    J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
    J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
    Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
    J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
    Prasad V; Kaestner V; Mailankody S
    JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
    [No Abstract]   [Full Text] [Related]  

  • 25. A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing.
    Zhu L; Huang Y; Fang X; Liu C; Deng W; Zhong C; Xu J; Xu D; Yuan Y
    J Mol Diagn; 2018 Mar; 20(2):225-231. PubMed ID: 29277635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
    Overman MJ; McDermott R; Leach JL; Lonardi S; Lenz HJ; Morse MA; Desai J; Hill A; Axelson M; Moss RA; Goldberg MV; Cao ZA; Ledeine JM; Maglinte GA; Kopetz S; André T
    Lancet Oncol; 2017 Sep; 18(9):1182-1191. PubMed ID: 28734759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
    Le DT; Durham JN; Smith KN; Wang H; Bartlett BR; Aulakh LK; Lu S; Kemberling H; Wilt C; Luber BS; Wong F; Azad NS; Rucki AA; Laheru D; Donehower R; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Greten TF; Duffy AG; Ciombor KK; Eyring AD; Lam BH; Joe A; Kang SP; Holdhoff M; Danilova L; Cope L; Meyer C; Zhou S; Goldberg RM; Armstrong DK; Bever KM; Fader AN; Taube J; Housseau F; Spetzler D; Xiao N; Pardoll DM; Papadopoulos N; Kinzler KW; Eshleman JR; Vogelstein B; Anders RA; Diaz LA
    Science; 2017 Jul; 357(6349):409-413. PubMed ID: 28596308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
    Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
    J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microsatellite Instability as a Biomarker for PD-1 Blockade.
    Dudley JC; Lin MT; Le DT; Eshleman JR
    Clin Cancer Res; 2016 Feb; 22(4):813-20. PubMed ID: 26880610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
    N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
    Venderbosch S; Nagtegaal ID; Maughan TS; Smith CG; Cheadle JP; Fisher D; Kaplan R; Quirke P; Seymour MT; Richman SD; Meijer GA; Ylstra B; Heideman DA; de Haan AF; Punt CJ; Koopman M
    Clin Cancer Res; 2014 Oct; 20(20):5322-30. PubMed ID: 25139339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics.
    Imai K; Yamamoto H
    Carcinogenesis; 2008 Apr; 29(4):673-80. PubMed ID: 17942460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors.
    Buhard O; Cattaneo F; Wong YF; Yim SF; Friedman E; Flejou JF; Duval A; Hamelin R
    J Clin Oncol; 2006 Jan; 24(2):241-51. PubMed ID: 16330668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
    Umar A; Boland CR; Terdiman JP; Syngal S; de la Chapelle A; Rüschoff J; Fishel R; Lindor NM; Burgart LJ; Hamelin R; Hamilton SR; Hiatt RA; Jass J; Lindblom A; Lynch HT; Peltomaki P; Ramsey SD; Rodriguez-Bigas MA; Vasen HF; Hawk ET; Barrett JC; Freedman AN; Srivastava S
    J Natl Cancer Inst; 2004 Feb; 96(4):261-8. PubMed ID: 14970275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
    Boland CR; Thibodeau SN; Hamilton SR; Sidransky D; Eshleman JR; Burt RW; Meltzer SJ; Rodriguez-Bigas MA; Fodde R; Ranzani GN; Srivastava S
    Cancer Res; 1998 Nov; 58(22):5248-57. PubMed ID: 9823339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
    Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L
    Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
    Trullas A; Delgado J; Genazzani A; Mueller-Berghaus J; Migali C; Müller-Egert S; Zander H; Enzmann H; Pignatti F
    ESMO Open; 2021 Jun; 6(3):100145. PubMed ID: 33940347
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.